Inhibitex, Inc.

The Texas A&m University System

Universitá Degli Studi Di Pavia

Paul Domanski

Joseph M Patti

Jeff T Hutchins

Andrea Hall

Pratiksha Patel

Magnus A Hook

Yi Xu

Pietro Speziale

Livia Visal

Fabrizia Casolini

Pratisksha Patel

Peter Syribeys

Andrea c/o Inhibitex Inc Hall

Jeff T c/o Inhibitex Inc Hutchins

Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability ofClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.

Monoclonal antibodies to the CLFA protein and method of use in treating infections

Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to bothandbacteria and which can thus be used in the prevention and treatment of infections caused by both of these types of bacteria. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the proteins are advantageous because they are cross-reactive and may thus be administered to patients so as to reduce or prevent severe infection by staphylococcal bacteria of more than one species. Antibodies generated in this manner have also been shown to exhibit displacement activity and can thus be utilized advantageously in methods wherein these antibodies will be administered to patients having pre-existing staphylococcal infections because of the ability to displace bacterial proteins from binding sites on the extracellular matrix. Finally, a method of identifying, isolating and utilizing displacing antibodies is also provided.

Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use

Monoclonal antibodies which can bind to the Fnbp protein ofand which are generated from a peptide from the D2 region of fibronectin binding protein B (Fnbp) ofare provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as. The monoclonal antibodies of the invention are advantageous in that they bindin high affinity and thus can be useful in the prevention of the adherence of staph bacteria to host cells by impairing or inhibiting the ability ofFnbp to bind to fibronectin. Kits and methods of utilizing the monoclonal antibodies of the invention are also provided.

Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections

Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections

Growing community of inventors

Atlanta, GA, United States of America

Paul Domanski